Contineum Therapeutics, Inc. (CTNM)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
17.05 USD
-0.20
(-1.159%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 17.05 |
Hot Take ↕ | Aug. 22, 2026, 2:10 a.m. EDT
The investment case for Contineum Therapeutics is currently defined by a stark disconnect between optimistic analyst targets and deteriorating market reality. While analysts project a 45% upside to $22.86, the stock has already erased nearly half its value over the last year, trading well below its book value of $6.37. The company is burning cash aggressively with negative free cash flow and no path to profitability visible in the near term, supported by a negative return on equity. Crucially, the options market is screaming caution; the heavy concentration of put open interest at deep strikes acts as a self-fulfilling prophecy for volatility, while the absence of call buying above the current price leaves no cushion for a rally. With no dividend to provide income and a balance sheet showing significant operational burn, the risk-reward profile remains skewed toward capital preservation rather than growth participation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.127818 |
| AutoARIMA | 0.133122 |
| AutoETS | 0.133122 |
| AutoTheta | 0.134325 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 5.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.128 |
| Excess Kurtosis | -1.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.743 |
| Market Cap | 641,440,256 |
| Forward P/E | -9.49 |
| Beta | 0.74 |
| Website | https://www.contineum-tx.com |
As of Aug. 22, 2026, 2:10 a.m. EDT: Speculators are heavily positioned for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes $2.50 and $10.00) expiring in late August and December. This 'insurance' positioning suggests a fear of significant further declines. Conversely, call activity is sparse and dominated by low-strike or ATM positions, with negligible volume in strikes above the current price, indicating a lack of speculative bullish momentum.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5443151 |
| Address1 | 3,565 General Atomics Court |
| Address2 | Suite 200 |
| All Time High | 22.0 |
| All Time Low | 3.35 |
| Ask | 17.08 |
| Ask Size | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 640,250 |
| Average Daily Volume3 Month | 429,837 |
| Average Volume | 429,837 |
| Average Volume10Days | 640,250 |
| Beta | 0.741 |
| Bid | 17.09 |
| Bid Size | 1 |
| Book Value | 6.372 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 17.05 |
| Current Ratio | 37.171 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 17.4 |
| Day Low | 16.93 |
| Debt To Equity | 2.743 |
| Display Name | Contineum Therapeutics |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | -65,996,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.235 |
| Enterprise Value | 411,463,296 |
| Eps Current Year | -1.55571 |
| Eps Forward | -1.79714 |
| Eps Trailing Twelve Months | -1.72 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.7976 |
| Fifty Day Average Change | 2.2523994 |
| Fifty Day Average Change Percent | 0.15221384 |
| Fifty Two Week Change Percent | 54.43151 |
| Fifty Two Week High | 17.51 |
| Fifty Two Week High Change | -0.460001 |
| Fifty Two Week High Change Percent | -0.026270758 |
| Fifty Two Week Low | 8.6 |
| Fifty Two Week Low Change | 8.449999 |
| Fifty Two Week Low Change Percent | 0.98255795 |
| Fifty Two Week Range | 8.6 - 17.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,712,323,800,000 |
| Float Shares | 27,823,084 |
| Forward Eps | -1.79714 |
| Forward P E | -9.487296 |
| Free Cashflow | -35,136,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 51 |
| Fullday Change | -0.200001 |
| Fullday Change Percent | -1.15942 |
| Fullday Price | 17.05 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00524 |
| Held Percent Institutions | 0.931 |
| Implied Shares Outstanding | 37,621,132 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-04-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California. |
| Long Name | Contineum Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 641,440,256 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_558548528 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -57,558,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 648,964,527 |
| Number Of Analyst Opinions | 7 |
| Open | 17.23 |
| Operating Cashflow | -53,006,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 333 5280 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 17.05 |
| Post Market Time | 1,787,947,805 |
| Previous Close | 17.25 |
| Price Eps Current Year | -10.959626 |
| Price Hint | 2 |
| Price To Book | 2.6757689 |
| Profit Margins | 0.0 |
| Quick Ratio | 36.247 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.375 |
| Region | US |
| Regular Market Change | -0.200001 |
| Regular Market Change Percent | -1.15942 |
| Regular Market Day High | 17.4 |
| Regular Market Day Low | 16.93 |
| Regular Market Day Range | 16.93 - 17.4 |
| Regular Market Open | 17.23 |
| Regular Market Previous Close | 17.25 |
| Regular Market Price | 17.05 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 477,838 |
| Return On Assets | -0.19150999 |
| Return On Equity | -0.28004998 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 32,958,632 |
| Shares Percent Shares Out | 0.0621 |
| Shares Short | 2,336,664 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,443,643 |
| Short Name | Contineum Therapeutics, Inc. |
| Short Percent Of Float | 0.0713 |
| Short Ratio | 6.78 |
| Source Interval | 15 |
| State | CA |
| Symbol | CTNM |
| Target High Price | 28.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 23.42857 |
| Target Median Price | 24.0 |
| Total Cash | 236,551,008 |
| Total Cash Per Share | 6.288 |
| Total Debt | 6,574,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.72 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.33205 |
| Two Hundred Day Average Change | 3.717949 |
| Two Hundred Day Average Change Percent | 0.278873 |
| Type Disp | Equity |
| Volume | 477,838 |
| Website | https://www.contineum-tx.com |
| Zip | 92,121 |